Cantel Medical (Little Falls, New Jersey) said that its Minntech subsidiary will relocate all of its remaining Dutch manufacturing operations to the U.S. This action is part of Cantel's continuing effort to reduce operating costs and leverage the existing infrastructure of its Minntech operations in Minneapolis.
The elimination of the Dutch manufacturing operations will lead to the discontinuance of onsite material management, quality assurance, finance and accounting, human resources and some customer service functions.
Minntech will continue to maintain a strong marketing, sales, service and technical support presence based in Holland to serve customers throughout Europe, the Middle East and Africa.
Cantel makes infection prevention and control products for the healthcare market.
Nasdaq to continue listing Vermillion
Vermillion (Fremont, California), a molecular diagnostics company, said the Nasdaq listing qualifications panel has informed it that the panel has determined to continue the listing of the company's securities on the Nasdaq capital market, subject to compliance by the company with marketplace rule 4310(c)(3) by Sept. 22. According to marketplace rule 4310(c)(3), the company is required to maintain stockholders' equity of at least $2.5 million or comply with one of the alternative listing criteria.
Vermillion makes diagnostic tests.